Adjusted changes in haemodynamic parameters in the V+A and in the V+T groups
| V+A group (n=48) | V+T group (n=49) | Between-group difference | p | ||
| SBP | Baseline | 155±16 | 155±17 | ||
| (mm Hg) | End of study | 137±21* | 138±16* | ||
| End of study† | 138 >(132 to 143) | 138 (133 to 143) | −0.7 (−7.9 to 6.5) | 0.85 | |
| DBP | Baseline | 88±11 | 88±12 | ||
| (mm Hg) | End of study | 79±13* | 80±12* | ||
| End of study† | 79 (76 to 82) | 81 (77 to 84) | −1.5 (−5.9 to 3.0) | 0.52 | |
| Heart rate | Baseline | 69±10 | 70±11 | ||
| (bpm) | End of study | 69±14 | 68±11 | ||
| End of study† | 69 (67 to 72) | 68 (68 to 69) | 1.6 (−2.6 to 5.7) | 0.45 | |
| AI | Baseline | 92.5±11.7 | 91.8±13.0 | ||
| (%) | End of study | 87.3±15.9* | 88.7±13.1 | ||
| End of study† | 86.2 (83.0 to 89.4) | 88.5 (85.3 to 91.7) | −2.3 (2.2 to 6.9) | 0.31 | |
| AI@75 | Baseline | 87.2±12.1 | 89.8±11.0 | ||
| (%) | End of study | 82.2±17.9* | 85.8±11.2* | ||
| End of study† | 83.8 (80.8 to 86.9) | 85.5 (82.4 to 88.5) | −1.6 (−6.0 to 2.7) | 0.46 | |
| Central BP | Baseline | 162±24 | 164±21 | ||
| (mm Hg) | End of study | 145±26* | 149±24* | ||
| End of study† | 147 (140 to 153) | 149 (143 to 155) | −2.2 (−11.2 to 6.7) | 0.62 |
Data are expressed as the mean±SD or mean (95% CI).
*p <0.01 versus baseline (paired t-test) and **p <0.05 versus baseline (paired t-test).
†The least square means (95% CI) and p values were derived from ANCOVA adjusted for age, sex and each baseline value.
ANCOVA, analysis of covariance; AI, augmentation index; AI@75, AI adjusted for a heart rate of 75 beats per minute; BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure; V+A, valsartan with aliskiren; V+T, valsartan with trichlormethiazide.